CDKN2A and acute lymphoblastic leukemia: This study aimed to explore the association between CDKN2A/B deletion and prognosis in pediatric ALL patients, with the goal of providing a new perspective for clinical treatment, risk stratification and prognostic assessment in pediatric ALL patients.